Skip to main content

Select Drug Profiles

ASH 2017 - Chronic Lymphocytic Leukemia

Efficacy and Safety of Bendamustine and Rituximab as First Salvage Treatment in CLL: Results of the GIMEMA-ERIC LLC1315 Study

ASH 2017 - Chronic Lymphocytic Leukemia

Phase 1/2 Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL

ASH 2017 - Chronic Lymphocytic Leukemia

Randomized Trial of Ibrutinib versus Ibrutinib plus Rituximab in Patients with CLL

ASH 2017 - Chronic Lymphocytic Leukemia

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

ASH 2017 - Chronic Lymphocytic Leukemia

Combined Venetoclax and Ibrutinib for Patients with Previously Untreated, High-Risk CLL and Relapsed/Refractory CLL: A Phase 2 Trial

ASH 2017 - Chronic Lymphocytic Leukemia

A Multicenter, Phase 2 Study of Ibrutinib plus FCR as Frontline Therapy for Younger Patients with CLL

ASH 2017 - Chronic Lymphocytic Leukemia

Initial Results of the Phase 2 Treatment-Naïve Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL

ASH 2017 - Chronic Lymphocytic Leukemia

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: Updated Results from the Phase 1/2 ACE-CL-001 Study

ASH 2017 - Chronic Lymphocytic Leukemia

Long-Term Follow-Up of ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel in Patients with Refractory, Aggressive NHL

ASH 2017 - Chronic Lymphocytic Leukemia

Phase 2 Study of Brentuximab Vedotin plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma

Page 77 of 244
Results 761 - 770 of 2434